Diligence memo · auto-generated · as of July 2, 2026
Ophidion Inc.
Ophidion Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Ophidion Inc. operates in Pharmaceuticals, based in Bethlehem.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ophidion Inc. has raised $4.0M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.7M on 2019-10-03.
Most recent recorded round closed around 2024-09-17.
Valuation (modeled)modeled
Provath models Ophidion Inc. at approximately $2.8M (range $495K–$7.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.29× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 21 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 38% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.